Invest in IPO

Divis Laboratories Ltd

  • BSE Code : 532488
  • NSE Symbol : DIVISLAB
  • ISIN : INE361B01024
  • Industry :PHARMACEUTICALS - INDIAN - BULK DRUGS

up-arrow 6,025.50 65.00(1.09%)

Open Price ()

5,841.50

Prev. Close ()

5,960.50

Volume (No’s)

449,984

Market Cap ()

158,232.55

Low Price ()

5,841.50

High Price ()

6,055.50

 

Board Meetings

Start Date End Date Purpose
08-May-2025 17-May-2025 Divis Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2025 inter alia to consider and approve Audited Financial Results for the Quarter and Year ended March 31 2025 and recommend Dividend for FY2024-25 if any.
23-Jan-2025 03-Feb-2025 DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2025 inter alia to consider and approve standalone and consolidated unaudited financial results of the Company for the quarter and nine months ended December 31 2024 as per enclosed attachment. (As per BSE Announcement Dated on 03/02/2025)
29-Oct-2024 09-Nov-2024 DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2024 inter alia to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter and half year ended September 30 2024. Submission of financial results for the quarter and half year ended September 30, 2024. (As Per BSE Announcement Dated on 09.11.2024)
25-Jul-2024 03-Aug-2024 DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2024 inter alia to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended June 30 2024. As per enclosed letter. Further to our intimation dated July 25, 2024, we would like to inform that the Board of Directors of the Company at its meeting held on August 03, 2024 has approved the unaudited financial results for the quarter ended June 30, 2024. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following: 1. Statement of standalone unaudited financial results for the quarter ended June 30, 2024 and Limited Review Report of the Statutory Auditors thereon. 2. Statement of consolidated unaudited financial results for the quarter ended June 30, 2024 and Limited Review Report of the Statutory Auditors thereon. 3. Press release on the financial results of the Company. Read less.. (As Per BSE Announcement Dated on 03.08.2024)
15-May-2024 25-May-2024 DIVIs LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2024 inter alia to consider and approve Audited financial results for the quarter and year ended March 31 2024 and recommend dividend fi any on the equity shares of the Company for the financial year 2023-24. As per enclosed letter. (As Per BSE Announcement Dated on 25.05.2024)

Copyright © 2024 Arihant Capital Markets Ltd. All rights Reserved.

Designed,Developed and Content powered by CMOTS Infotech (ISO 9001:2015 certified)

x
  • QR-CodeNew